UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

Oncotarget, 2018-05, Vol.9 (40), p.26032-26045

2018

Volltextzugriff (PDF)

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

Proceedings of the National Academy of Sciences - PNAS, 2013-07, Vol.110 (29), p.11988-11993

2013

Volltextzugriff (PDF)

Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics

Bioorganic & medicinal chemistry, 2023-08, Vol.91, p.117402-117402, Article 117402

2023

Volltextzugriff (PDF)

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice

Journal of hepatology, 2017-12, Vol.67 (6), p.1194-1203

2017

Volltextzugriff (PDF)

Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity

Neuro-oncology (Charlottesville, Va.), 2020-04, Vol.22 (4), p.563-574

2020

Volltextzugriff (PDF)

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.615-625

2019

Volltextzugriff (PDF)

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

Investigational new drugs, 2018-06, Vol.36 (3), p.458-467

2018

Volltextzugriff (PDF)

Consequences of Mammalian Target of Rapamycin Inhibition on Adeno-Associated Virus Hepatic Transduction Efficacy

Human gene therapy, 2021-10, Vol.32 (19-20), p.1242

2021

Volltextzugriff (PDF)

Merkel Cell Carcinoma Therapeutic Update

Current Treatment Options in Oncology, 2016-07, Vol.17 (7), p.36-36, Article 36

2016

Volltextzugriff (PDF)

The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma

Cancer letters, 2017-08, Vol.400, p.110-116

2017

Volltextzugriff (PDF)

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Leukemia, 2013-03, Vol.27 (3), p.586-594

2013

Volltextzugriff (PDF)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma

mBio, 2019-02, Vol.10 (1)

2019

Volltextzugriff (PDF)

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Cancer chemotherapy and pharmacology, 2017-08, Vol.80 (2), p.261-273

2017

Volltextzugriff (PDF)

Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

Breast cancer research and treatment, 2018-08, Vol.170 (3), p.499-506

2018

Volltextzugriff (PDF)

The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity

Neuro-oncology (Charlottesville, Va.), 2017-10, Vol.19 (10), p.1361-1371

2017

Volltextzugriff (PDF)

mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors

Journal of thrombosis and haemostasis, 2019-01, Vol.17 (1), p.169-182

2019

Volltextzugriff (PDF)

Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment

Cells (Basel, Switzerland), 2023-02, Vol.12 (4), p.547

2023

Volltextzugriff (PDF)

mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms

Breast cancer research and treatment, 2014-04, Vol.144 (2), p.287-298

2014

Volltextzugriff (PDF)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma

Cancers, 2019-07, Vol.11 (7), p.930

2019

Volltextzugriff (PDF)

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth

Oncotarget, 2016-02, Vol.7 (6), p.6576-6592

2016

Volltextzugriff (PDF)

Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis

International journal of biological sciences, 2018-01, Vol.14 (10), p.1221-1231

2018

Volltextzugriff (PDF)

Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC–MS/MS

Biomedical chromatography, 2017-03, Vol.31 (3), p.np-n/a

2017

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Mln0128
(22)
Science & Technology
(21)
Life Sciences & Biomedicine
(20)
Humans
(17)
Oncology
(12)
Animals
(11)
Tor Protein
(11)
Tor Serine-Threonine Kinases - Antagonists & Inhibitors
(11)
Pyrimidines - Pharmacology
(10)
Benzoxazoles - Pharmacology
(9)
Mice
(9)
Cell Line, Tumor
(8)
Protein Kinase Inhibitors - Pharmacology
(8)
Cell Proliferation
(7)
Cell Proliferation - Drug Effects
(7)
Female
(7)
Rapamycin
(7)
Tumors
(7)
Apoptosis
(6)
Medicine
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice

Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

Consequences of Mammalian Target of Rapamycin Inhibition on Adeno-Associated Virus Hepatic Transduction Efficacy

Merkel Cell Carcinoma Therapeutic Update

The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity

mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors

Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment

mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth

Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis

Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC–MS/MS

Suchergebnisse filtern